Marion Harris

Summary

Affiliation: Genetic Health Services Victoria
Country: Australia

Publications

  1. ncbi Monoclonal antibodies as therapeutic agents for cancer
    Marion Harris
    Murdoch Children s Research Institute, Royal Children s Hospital, Parkville, Victoria, Australia
    Lancet Oncol 5:292-302. 2004
  2. ncbi Controversies and ethical issues in cancer-genetics clinics
    Marion Harris
    Genetic Health Services Victoria, Murdoch Children s Research Institute, Royal Children s Hospital, Parkville, Victoria 3050, Australia
    Lancet Oncol 6:301-10. 2005
  3. ncbi Optimal selection of individuals for BRCA mutation testing: a comparison of available methods
    Paul A James
    Familial Cancer Centre, Murdoch Children s Research Institute, Melbourne, Australia
    J Clin Oncol 24:707-15. 2006
  4. ncbi Re: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Finlay Macrae
    J Natl Cancer Inst 97:936-7; author reply 937-8. 2005

Detail Information

Publications4

  1. ncbi Monoclonal antibodies as therapeutic agents for cancer
    Marion Harris
    Murdoch Children s Research Institute, Royal Children s Hospital, Parkville, Victoria, Australia
    Lancet Oncol 5:292-302. 2004
    ..Positive results for other antibodies in various stages of clinical development provide hope that anticancer antibodies will have an effect on clinical oncology practice in the next 10 years...
  2. ncbi Controversies and ethical issues in cancer-genetics clinics
    Marion Harris
    Genetic Health Services Victoria, Murdoch Children s Research Institute, Royal Children s Hospital, Parkville, Victoria 3050, Australia
    Lancet Oncol 6:301-10. 2005
    ....
  3. ncbi Optimal selection of individuals for BRCA mutation testing: a comparison of available methods
    Paul A James
    Familial Cancer Centre, Murdoch Children s Research Institute, Melbourne, Australia
    J Clin Oncol 24:707-15. 2006
    ..We examined the performance of six different methods with the aim of identifying an optimal strategy for selecting individuals for mutation testing in clinical practice...
  4. ncbi Re: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Finlay Macrae
    J Natl Cancer Inst 97:936-7; author reply 937-8. 2005